Diffuse high intensity PD-L1 staining in thymic epithelial tumors

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 500-508

  Padda, Sukhmani K ^a   Riess, Jonathan W ^b   Schwartz, Erich J ^a   Tian, Lu ^a   Kohrt, Holbrook E ^a   Neal, Joel W ^a   West, Robert B ^a   Wakelee, Heather A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATIONAL STUDY; EPITHELIUM TUMOR; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMIC EPITHELIAL TUMOR; THYMOMA; TISSUE MICROARRAY; TREND STUDY; WORLD HEALTH ORGANIZATION; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; THYMUS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS; SURVIVAL RATE; THYMUS GLAND; THYMUS NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84926420934     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000429     Document Type: Article

References (43)

1. Engels EA, Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010 5 S260 S265
2. Miller JF, The golden anniversary of the thymus. Nat Rev Immunol 2011 11 489 495
3. Hsieh CS, Lee HM, Lio CW, Selection of regulatory T cells in the thymus. Nat Rev Immunol 2012 12 157 167
4. Margaritora S, Cesario A, Cusumano G, Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010 89 245 52; discussion 252
5. Thompson CA, Steensma DP, Pure red cell aplasia associated with thymoma: Clinical insights from a 50-year single-institution experience. Br J Haematol 2006 135 405 407
6. Weksler B, Nason KS, Mackey D, Gallagher A, Pennathur A, Thymomas and extrathymic cancers. Ann Thorac Surg 2012 93 884 888
7. Hoffacker V, Schultz A, Tiesinga JJ, Thymomas alter the T-cell subset composition in the blood: A potential mechanism for thymoma-Associated autoimmune disease. Blood 2000 96 3872 3879
8. Luther C, Poeschel S, Varga M, Melms A, Tolosa E, Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-Associated thymoma. J Neuroimmunol 2005 164 124 128
9. Ströbel P, Helmreich M, Menioudakis G, Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood 2002 100 159 166
10. Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 12 252 264
11. Taube JM, Klein A, Brahmer JR, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014 20 5064 5074
12. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 366 2443 2454
13. Ishida M, Iwai Y, Tanaka Y, Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 2002 84 57 62
14. Bleul CC, Boehm T, Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. Eur J Immunol 2001 31 2497 2503
15. Brown JA, Dorfman DM, Ma FR, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003 170 1257 1266
16. Nishimura H, Honjo T, Minato N, Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 2000 191 891 898
17. Keir ME, Latchman YE, Freeman GJ, Sharpe AH, Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 2005 175 7372 7379
18. Tsushima F, Yao S, Shin T, Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007 110 180 185
19. Zucchelli S, Holler P, Yamagata T, Roy M, Benoist C, Mathis D, Defective central tolerance induction in NOD mice: Genomics and genetics. Immunity 2005 22 385 396
20. Kononen J, Bubendorf L, Kallioniemi A, Tissue microarrays for high-Throughput molecular profiling of tumor specimens. Nat Med 1998 4 844 847
21. Nielsen TO, Hsu FD, O'Connell JX, Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003 163 1449 1456
22. Bigelow E, Bever KM, Xu H, Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp 2013
23. Kondo K, Yoshizawa K, Tsuyuguchi M, WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004 77 1183 1188
24. Herbst RS, Gordon MS, Fine GD, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013 31 suppl; abstr 3000
25. Hamid O, Robert C, Daud A, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 369 134 144
26. Velcheti V, Rimm DL, Schalper KA, Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J Thorac Oncol 2013 8 803 805
27. Mansfield AS, Roden AC, Peikert T, B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014 9 1036 1040
28. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S, Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007 56 1173 1182
29. Muenst S, Schaerli AR, Gao F, Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014 146 15 24
30. Droeser RA, Hirt C, Viehl CT, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013 49 2233 2242
31. Velcheti V, Schalper KA, Carvajal DE, Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014 94 107 116
32. Zhang Y, Wang L, Li Y, Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014 7 567 573
33. McLaughlin J, Schalper KA, Carvajal-Hausdorf DE, Quantitative measurement of PD-L1 protein in non-small cell lung cancer using different antibodies 2014 Santa Monica, CA Presented at the IASLC 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting
34. Brahmer JR, Horn L, Gandhi L, Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. J Clin Oncol 2014 32 suppl; abstr 8112 5s
35. Hodi FS, Sznol M, Kluger H, Long-Term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 2014 32 suppl; abstr 9002 5s
36. Rizvi NA, Chow LQM, Dirix LY, Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014 32 suppl; abstr TPS8123 5s
37. Powles T, Vogelzang NJ, Fine GD, Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014 32 suppl; abstr 5011 5s
38. Zhang L, Conejo-Garcia JR, Katsaros D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 348 203 213
39. Galon J, Costes A, Sanchez-Cabo F, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 1960 1964
40. Detterbeck FC, Zeeshan A, Thymoma: Current diagnosis and treatment. Chin Med J (Engl) 2013 126 2186 2191
41. Loehrer PJ Sr, Chen M, Kim K, Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. J Clin Oncol 1997 15 3093 3099
42. Lemma GL, Lee JW, Aisner SC, Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011 29 2060 2065
43. Topalian SL, Sznol M, McDermott DF, Survival, durable tumor remission, and long-Term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 32 1020 1030